New

Hope to launch Covovax by September 2021: Adar Poonawalla

PTI New Delhi | Updated on March 27, 2021

Adar Poonawalla, CEO, Serum Institute of India Ltd DHIRAJ SINGH

Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of Covid-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year.

In August 2020, American vaccine company Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its Covid-19 vaccine candidate, in low and middle-income countries and India.

"Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #COVID19 and has an overall efficacy of 89%. Hope to launch by September 2021!," Poonawalla said in a tweet. PTI AKT ANU ANU

Published on March 27, 2021

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Covid-19
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.